Gene expression profile and signaling pathways in MCF-7 breast cancer cells mediated by acyl-CoA synthetase 4 overexpression by Castillo, Ana Fernanda et al.
Volume 3 • Issue 2 • 1000120TranscriptomicsISSN: 2329-8936 TOA, an open access journal
Tr
an
sc
rip
tom
ics: Open Access
ISSN: 2329-8936
Transcriptomics: Open Access
Castillo et al., Transcriptomics 2015, 3:2
http://dx.doi.org/10.4172/2329-8936.1000120
Research Article Open Access
Gene Expression Profile and Signaling Pathways in MCF-7 Breast Cancer 
Cells Mediated by Acyl-CoA Synthetase 4 Overexpression
Ana F Castillo#, Ulises D Orlando#, Paula Lopez, Angela R Solano, Paula M. Maloberti and Ernesto J Podesta*
Biomedical Research Institute, Inbiomed, Department of Biochemistry, School of Medicine University of Buenos Aires, CABA, C1121ABG, Argentina
#equally Contributed
Abstract
Aim: Breast cancer comprises a heterogeneous group of diseases that vary in morphology, biology, behavior and 
response to therapy. Previous studies have identified an acyl-CoA synthetase 4 (ACSL4) gene-expression pattern 
correlated with very aggressive tumors. In particular, we have used the tetracycline Tet-Off system to stably transfect 
non-aggressive breast cancer MCF-7 cells and developed a stable line overexpressing ACSL4 (MCF-7 Tet-Off/ACSL4). 
As a result, we have proven that cell transfection solely with ACSL4 cDNA renders a highly aggressive phenotype in 
vitro and results in the development of growing tumors when injected into nude mice. Nevertheless, and in spite 
of widespread consensus on the role of ACSL4 in mediating an aggressive phenotype in breast cancer, the early 
steps through which ACSL4 increases tumor growth and progression have been scarcely described and need further 
elucidation. For this reason, the goal of this work was to study the gene expression profile and the signaling pathways 
triggered by ACSL4 overexpression in the mechanism that leads to an aggressive phenotype in breast cancer.
Methods: We have performed a massive in-depth mRNA sequencing approach and a reverse-phase protein array 
using MCF-7 Tet-Off/ACSL4 cells as a model to identify gene expression and functional proteomic signatures specific 
to ACSL4 overexpression. 
Results and Conclusion: The sole expression of ACSL4 displays a distinctive transcriptome and functional 
proteomic profile. Furthermore, gene networks most significantly upregulated in breast cancer cells overexpressing 
ACSL4 are associated to the regulation of embryonic and tissue development, cellular movement and DNA replication 
and repair. In conclusion, ACSL4 is an upstream regulator of tumorigenic pathways. Because an aggressive tumor 
phenotype appears in the early stages of metastatic progression, the previously unknown mediators of ACSL4 might 
become valuable prognostic tools or therapeutic targets in breast cancer.
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Introduction
Breast cancer remains the second most important cause of death 
(by cancer) among women [1]. Patients who cannot be cured are those 
in whom breast cancer has metastasized, that is, breast cancer cells 
have migrated and invaded other organs such as lung and bone. As 
no effective therapies are currently available, aggressive breast cancer 
constitutes a key field for both researchers and clinicians. It has been 
shown that both in breast cancer cell lines and in tumor samples the 
expression of acyl-CoA synthetase 4 (ACSL4) is directly correlated with 
aggressiveness in breast cancer and inversely correlated with estrogen 
receptor alpha (ERα) levels [2-4]. ACSL4 belongs to a five-member 
family of enzymes that esterifies mainly arachidonic acid (AA) into 
acyl-CoA [2-5]. Unlike the other ACSL isoforms, ACSL4 is encoded 
on the X chromosome and its expression is highest in adrenal cortex, 
ovary and testis [6-10], as well as in mouse and human cerebellum 
and hippocampus [11]. Studies on the physiological functions of 
ACSL4 have revealed possible roles in polyunsaturated fatty acid 
metabolism in brain, in steroidogenesis, in eicosanoid metabolism 
related to apoptosis and embryogenesis [8-14]. ACSL4 expression 
has also been associated with non-physiological functions such as 
mental retardation disorder [15,16] and cancer [2,3,17,18]. ACSL4 was 
first associated with cancer due to its abnormal expression in colon 
and hepatocellular carcinoma. Increased ACSL4 expression, both 
at mRNA and protein levels [18], in colon adenocarcinoma cells has 
been associated with the inhibition of apoptosis and an increase in cell 
proliferation when compared to adjacent normal tissue. ACSL4 has 
also been suggested as a predictive factor for drug resistance in breast 
cancer patients receiving adriamycin-containing chemotherapy [19]. 
We have demonstrated a positive correlation of ACSL4 expression and 
aggressiveness in breast cancer cell lines, with the highest expression 
found in metastatic lines derived from triple-negative tumor breast 
cancer (MDA-MB-231 and Hs578T) [3]. Functionally, we have found 
that ACSL4 is part of the mechanism responsible for increased breast 
cancer cell proliferation, invasion and migration, both in vitro and in 
vivo [3,4]. We have further demonstrated that ACSL4 can be silenced to 
reduce cell line aggressiveness. The role of ACSL4 in the development 
of growing tumors found further support when tumor growth was 
inhibited through the inhibition of ACSL4 expression [5]. However, 
even if the role of ACSL4 in mediating an aggressive phenotype in 
breast cancer is well accepted, its underlying mechanisms have been 
scarcely explored. For this reason, the goal of this work was to study the 
gene expression profile and the signaling pathways triggered by ACSL4 
overexpression in the mechanism that leads to an aggressive phenotype 
in breast cancer. Thus, we have performed a massive in-depth mRNA 
sequencing approach and a reverse-phase protein array using ACSL4-
overexpressing MCF-7 cells, as a model to identify gene expression and 
functional proteomic signatures specific to ACSL4 overexpression.
Materials and Methods
Cell culture
The human breast cancer cell line was generously provided by Dr. 
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Vasilios Papadopoulos (Research Institute of the McGill University 
Health Centre, Montreal, Canada) and obtained from the Lombardi 
Comprehensive Cancer Center (Georgetown University Medical 
Center, Washington D.C., USA). The tetracycline-repressible MCF-7 
cell lines, designated MCF-7 Tet-Off empty vector, and MCF-7 Tet-
Off-induced repression of ACSL4, designated MCF-7 Tet-Off/ACSL4, 
were obtained previously in the laboratory [3]. The cell lines were 
maintained in Dulbecco’s modified Eagle (DMEM) medium (GIBCO, 
Invitrogen Corporation,Grand Island, NY, USA) supplemented with 
10% Fetal calf serum (PAA laboratories GmbH, Pasching, Austria) plus 
100 U/ml penicillin and 10 mg/ml streptomycin (GIBCO, Invitrogen 
Corporation,Grand Island, NY, USA). Doxycycline (Sigma Chemical 
Co.,St. Louis, MO, USA), a more stable tetracycline analogue, was used 
to regulate the expression of the Tet-Off system. Sterile and plastic 
material for tissue culture was from Orange Scientific (Braine-l’Alleud, 
Belgium). All other reagents were of the highest grade available. 
RNA-Seq sample preparation and sequencing
For each cell line, total RNA was extracted by Direct-zol RNA 
kit (Zymo Research, Irvine, CA, USA). RNA quality was assessed 
by agarose gel electrophoresis (visual absence of significant 28S and 
18S rRNA degradation) and by spectrophotometry. RNA-Seq was 
performed by Zymo Research facility performing PolyA enrichment 
of the RNA samples. HiSeq 2 x 50 bp paired-ends reads from RNA-
Seq of a human normal-tumor pair samples were analyzed first using 
the TopHat and Cufflinks software. TopHat (v2.0.6) was utilized 
for alignment of short reads to GRCh37, Cufflinks (v2.0.2) for 
isoform assembly and quantification, and commeRbund (v2.0.0) for 
visualization of differential analysis. Default parameters were used. The 
RNA-Seq quality control was performed using Dispersion, Volcano, 
MA, Density, PCA, Scatter and Box plots.
Quantitative reverse transcription-PCR (qRT-PCR) 
MCF-7 Tet-Off empty vector and MCF-7 Tet-Off/ACSL4 total 
RNA was extracted using Tri-Reagent (Molecular Research Center, 
Cincinnati, OH, USA) following the manufacturer’s instructions. Any 
residual genomic DNA was removed by treating RNA with DNase I 
(Invitrogen, Carlsbad, CA, USA) at room temperature for 15 min, 
which was subsequently inactivated by incubation with 2.5 mM EDTA 
for 10 min at 65°C. Two µg of total RNA were reverse transcribed 
using random hexamers and M-MLV Reverse Transcriptase (Promega, 
Madison, WI, USA) according to the manufacturer’s protocol. For real-
time PCR, gene specific primers were obtained from RealTimePrimers.
com (Elkins Park, PA, USA). Real-time PCR was performed using 
Applied Biosystems 7300 Real-Time PCR System and 20 µl of a solution 
containing 5 µl of cDNA, 10 µM forward and reverse primers, and 10 
µl of SYBR Select Master Mix (Applied Biosystems, Carlsbad, CA, 
USA) for each reaction. All reactions were performed in triplicate. 
Amplification was initiated by a 2-min preincubation at 50°C, 2-min 
incubation at 95°C, followed by 40 cycles at 95°C for 15 sec, 55°C for 
15 sec and 72°C for 1 min, terminating at 95°C for the last 15 sec. 
Gene mRNA expression levels were normalized to human 18S RNA 
expression, performed in parallel as endogenous control. Real-time 
PCR data were analyzed by calculating the 2−ΔΔCt value (comparative Ct 
method) for each experimental sample. 
David and Ingenuity Pathways Analysis
To identify the statistically significant biological functions and 
signaling pathways affected by the genes differentially expressed in 
our comparisons, we used Database for Annotation, Visualization and 
Integrated Discovery (DAVID) [20] and Ingenuity Pathways Analysis 
(IPA; Ingenuity Systems, Inc., Cambridge, MA, USA) [21]. IPA is the 
largest curated database and analysis system for understanding the 
signaling and metabolic pathways, molecular networks and biological 
processes that are most significantly changed in a dataset of interest. 
Ranking and significance of the biofunctions and the canonical 
pathways were tested by the p-value. Additionally, canonical pathways 
were ordered by the ratio (number of genes from the input data set that 
map to the pathway divided by the total number of molecules that exist 
in the canonical pathway). IPA also generated cellular networks where 
the differentially regulated genes were related according to previously 
known associations between genes or proteins, but independently of 
established canonical pathways. Top networks represent associative 
network functions based on a score that considers the –log (p-value), 
which aggregates the likelihood that genes in the network are found 
together due to random chance. 
Reverse phase protein assay (RPPA)
RPPA was performed in the RPPA Core Facility - Functional 
Proteomics from MD –Anderson Cancer Center, University of Texas, 
TX, USA. Cellular proteins were denatured by 1% SDS (with beta-
mercaptoethanol) and diluted in five 2-fold serial dilutions in dilution 
buffer (lysis buffer containing 1% SDS). Serial diluted lysates were 
arrayed on nitrocellulose-coated slides (Grace Biolab) by Aushon 2470 
Arrayer (Aushon BioSystems) [22].
Statistical Analysis
Data analysis was performed using GraphPad InStat Software 3.01 
(La Jolla, CA, USA). Statistical significance was determined by analysis 
of variance (ANOVA) followed by Tukey- Kramer Multiple Comparison 
Test and Spearman’s rank correlation coefficient was calculated using 
Social Science Statistics free statistics software.
Results and Discussion
Differential gene expression triggered by ACSL4 
As ACSL4 plays a crucial role in tumor growth, we have undertaken 
a systematic study to identify genes with tumorigenesis capacity and 
elucidate the underlying signaling mechanism. Toward understanding 
the capacity of ACSL4 in the regulation of tumorigenesis, we have 
previously reported the involvement of AA lipoxygenase and 
cyclooxygenase metabolites in the action of ACSL4 [3,4] and, in this 
report, we focus on the identification of ACSL4-responsive genes 
using the RNA-Seq in MCF-7 Tet-Off/ACSL4 compared with an 
MCF-7 Tet-Off empty vector. This system is particularly valuable 
in enabling both the overexpression and the specific inhibition of 
ACSL4 through doxycycline treatment and has been previously used 
to develop tumors in xenograft models [3,4]. Results show a total of 
26705366 RNA-Seq reads acquired from MCF-7 Tet-Off/ACSL4 and 
22258811 reads acquired from MCF-7 Tet-Off empty vector. We next 
aligned the sequence reads to a human genome reference (GRCh37) 
using TopHat version 2.0.6, with results rendering 93.30% of the 
MCF-7 Tet-Off/ACSL4 reads and 92.90% of the MCF-7 Tet-Off empty 
vector reads as successfully mapped. The resulting read alignments (file 
format: BAM) were then assembled through Cufflinks version 2.0.2 
for isoform assembly and quantification, and commeRbund (v2.0.0) 
for visualization of differential analysis (default parameters were 
used). The RNA-Seq quality control was performed using Dispersion, 
Volcano, MA, Density, PCA, Scatter and Box plots. Gene expression 
levels were determined by measuring the sum of fragments per kilobase 
of exon model per million of reads mapped (FPKM), analyzed in each 
exon. To acquire more accurate results, data were filtered out whenever 
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estimated FPKM values in both MCF-7 Tet-Off/ACSL4 and MCF-7 
Tet-Off empty vector samples were less than 1.0 (cf. an FPKM value of 
0.05 is commonly set as the lowest boundary of expression level). Only 
loci having a log2 (fold change) > 2 between MCF-7 Tet-Off/ACSL4 and 
MCF-7 Tet-Off empty vector were considered. Ultimately, we observed 
that, from 32247 successfully sequenced loci, 3944 were significantly 
and differentially expressed in MCF-7 Tet-Off/ACSL4 samples. Among 
them, 2501 were upregulated and 1443 were downregulated. ACSL4 
gene was one of the genes taken as a control of its overexpression and, 
as expected, it was one of the genes showing major differences between 
MCF-7 Tet-Off/ACSL4 and MCF-7 Tet-Off empty vector. Table 1 
shows the top genes which exhibit differential changes when ACSL4 is 
overexpressed. To determine the characteristic chromosomal location 
of genes controlled by ACSL4 expression, we used the CROC program 
[23] to examine the expression landscape by plotting the number of 
differentially expressed genes along the whole chromosomes. Results 
revealed that chromosome distribution patterns varied greatly with 
respect to gene density and, in particular, chromosome 1 showed the 
highest gene density among genes mapped (Figure S1). A total of 52 
clusters were found –chromosome 1 showed the highest number of 
clusters (8)-, while the number of genes in clusters was 181. 
Enriched functional categories of gene networks relating to 
the transcripts regulated by ACSL4 overexpression
To gain insights into biological cell properties, IPA was used to rank 
enriched functional categories of gene networks relating to the transcripts 
regulated in ACSL4-responsive gene sets acquired from the RNA-Seq 
data. The highest-scoring associated diseases and disorders are shown in 
Table 2, while cancer was the disease showing the lowest p-value among 
diseases and disorders. As a result, we verified 390 top biofunctions 
concerned with the ACSL4-induced transcriptome alteration in 
MCF-7 Tet-Off/ACSL4 cells. The most significantly tumorigenesis-
related biofunctions (only p-values under 0.01) are shown in 
Table 3. In agreement with our previous results regarding ACSL4 
effect on cell proliferation, invasion and migration [3,4], the top three 
biofunctions which were IPA-predicted to be increased in RNA-Seq 
data were cell movement migration and proliferation. Table S1 shows 
a detailed list of molecules altered in these biofunctions. Table 4 shows 
the top ten most significantly upregulated functions related to gene 
networks in the RNA-Seq –along with a list of the corresponding 
genes in each function network–, while Figure S2 shows the network 
corresponding to the top ten upregulated functions. DNA replication, 
GENES UPREGULATED
Name Gene Symbol Location Type(s) log2 fold change
NADPH oxidase 3 NOX3 cytoplasm enzyme 13.21
De-etiolated homolog 1 (Arabidopsis) DET1 nucleus other 10.97
Patched 2 PTCH2 plasma membrane transmembrane receptor 10.9
Wingless-type MMTV integration site family, member 6 WNT6 extracellular space other 6.74
Zinc finger, matrin-type 4 ZMAT4 nucleus other 5.02
Retinoic acid induced 2 RAI2 unknown other 4.75
Dual specificity phosphatase 18 DUSP18 cytoplasm phosphatase 4.69
Transcription factor B1, mitochondrial TFB1M cytoplasm transcription regulator 4.58
MAP/microtubule affinity-regulating kinase 1 MARK1 cytoplasm kinase 4.30
Interleukin 20 IL20 extracellular space cytokine 4.29
Fatty acyl CoA reductase 2 FAR2 cytoplasm enzyme 4.16
Ets homologous factor EHF nucleus transcription regulator 4.09
SH3-domain GRB2-like 3 SH3GL3 cytoplasm other 4.06
2'-5'-oligoadenylate synthetase 1, 40/46kDa OAS1 cytoplasm enzyme 4.05
Synaptotagmin XIII SYT13 plasma membrane transporter 3.85
Aldehyde oxidase 1 AOX1 cytoplasm enzyme 3.78
G protein, alpha inhibiting activity GNAI1 plasma membrane enzyme 3.78
FXYD domain containing ion transport regulator 5 FXYD5 plasma membrane ion channel 3.75
Cytochrome c oxidase subunit VIIb2 COX7B2 unknown unknown 3.73
Wingless-type MMTV integration site family, member 10A WNT10A extracellular space other 3.60
Interferon, alpha-inducible protein 6 IFI6 cytoplasm other 3.35
Sp6 transcription factor SP6 nucleus transcription regulator 3.35
Acyl-CoA oxidase 2, branched chain ACOX2 cytoplasm enzyme 3.31
Transforming growth factor, beta 2 TGFB2 extracellular space growth factor 3.22
Interleukin 24 IL24 extracellular space cytokine 3.15
GABA(A) receptor-associated protein like 1 GABARAPL1 cytoplasm other 2.54
FBJ murine osteosarcoma viral oncogene homolog FOS nucleus transcription regulator 2.41
Laminin, beta 1 LAMB1 extracellular space other 2.37
Nuclear receptor coactivator 4 NCOA4 nucleus transcription regulator 2.09
Phospholipase D1, phosphatidylcholine-specific PLD1 cytoplasm enzyme 2.09
v-Erb-b2 ERBB2 plasma membrane kinase 2.05
Fibroblast growth factor 11 FGF11 extracellular space other 2.04
Ret proto-oncogene RET plasma membrane kinase 2.04
Fibroblast growth factor receptor 1 FGFR1 plasma membrane kinase 2.04
Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) ITGA2 plasma membrane transmembrane receptor 2.02
Eukaryotic translation initiation factor 2-alpha kinase 2 EIF2AK2 cytoplasm kinase 1.94
Unc-51 like autophagy activating kinase 1 ULK1 cytoplasm kinase 1.83
Vascular endothelial growth factor A VEGFA extracellular space group 1.75
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GENES DOWNREGULATED
Name Gene Symbol Location Type(s) log2 fold change
Protein tyrosine phosphatase, non-receptor type 22 PTPN22 cytoplasm phosphatase -11.55
ADAM metallopeptidase with thrombospondin type 1 motif, 9 ADAMTS9 extracellular space peptidase -11.21
Prickle homolog 2 PRICKLE2 nucleus other -11.08
Neurotrophic tyrosine kinase, receptor, type 3 NTRK3 plasma membrane kinase -8.13
Contactin associated protein-like 3B CNTNAP3B unknown other -7.29
WNT inhibitory factor 1 WIF1 extracellular space other -4.75
Keratin, Type I cytoskeletal 20 CK20 (KRT20) cytoplasm other -4.22
Deiodinase, iodothyronine, type II DIO2 cytoplasm enzyme -3.62
Zinc finger protein 217 ZNF217 nucleus transcription regulator -3.41
Ca++-dependent secretion activator CADPS plasma membrane other -3.15
Table 1: Identification of significantly upregulated and downregulated genes by ACSL4 overexpression using RNA-Seq.
Figure 1: Real-time RT-PCR analysis of the top genes exhibiting differential 
changes in RNA-Seq when ACSL4 is overexpressed. Total RNA was isolated 
from MCF-7 Tet-Off empty vector and MCF-7 Tet-Off/ACSL4 cells, reverse 
transcribed and subjected to real-time PCR using specific primers. Each 
transcript expression level was normalized to human 18S RNA expression, 
performed in parallel as endogenous control. Real-time PCR data were analyzed 
by calculating the 2-∆∆Ct value (comparative Ct method) for each experimental 
sample. Relative mRNA expression levels are shown. Data are presented as 
mean ± standard deviation (SD).
Name of Diseases and Disorders  p-value # molecules
Cancer 5.74E-07 - 0.0191 530
Infectious Disease 4.56E-05 - 0.0174 136
Reproductive System Disease 7.35E-05 -1.87E-02 163
Dermatological Diseases and 
Conditions  8.42E-05 - 0.0141 74
Endocrine System Disorders 1.09E-04 - 0.0197 78
Table 2: Top associated diseases and disorders analyzed by IPA. Top significantly 
diseases and disorders concerned with the ACSL4-induced transcriptome 
alteration in MCF-7 Tet-Off/ACSL4 cells.
Category
Diseases or 
Functions 
Annotation
p-value
Predicted 
Activation 
State
Activation 
z-score
# 
Molecules
Cellular 
Movement cell movement 3.97E-07 Increased 4.685 182
Cellular 
Movement
migration of 
cells 4.65E-07 Increased 4.677 166
Cellular Growth 
and Proliferation
proliferation of 
cells 2.04E-06 Increased 2.390 295
Cellular Assembly 
and Organization
formation 
of cellular 
protrusions
7.15E-05 Increased 3.830 73
Cellular Assembly 
and Organization
microtubule 
dynamics 1.48E-04 Increased 4.169 94
Cellular Assembly 
and Organization
organization 
of 
cytoskeleton
1.89E-04 Increased 3.662 107
Gene
Expression transactivation 3.17E-04 Increased 3.318 59
Cellular Assembly 
and Organization
organization 
of cytoplasm 3.73E-04 Increased 3.714 113
Carbohydrate 
Metabolism
sulfation of 
polysaccharide 4.39E-04 Increased 2.132 5
Gene
Expression
transactivation 
of RNA 9.23E-04 Increased 3.718 54
Cancer proliferation of cancer cells 1.05E-03 Increased 2.009 37
Cellular Assembly 
and Organization
formation 
of plasma 
membrane 
projections
1.20E-03 Increased 2.128 49
Cellular Growth 
and Proliferation
proliferation 
of connective 
tissue cells
1.45E-03 Increased 2.628 54
Cellular 
Development
branching of 
cells 1.60E-03 Increased 3.043 17
Cellular 
Movement
cell movement 
of tumor cell 
lines
2.20E-03 Increased 2.034 67
Cellular 
Movement
migration of 
tumor cell 
lines
2.26E-03 Increased 2.139 55
Cellular 
Movement
cell movement 
of tumor cells 2.41E-03 Increased 2.530 19
Cell Morphology
shape change 
of tumor cell 
lines
5.81E-03 Increased 2.180 16
Cellular 
Development
differentiation 
of stem cells 8.78E-03 Increased 2.540 21
Cancer
prostate 
cancer and 
tumors
1.17E-02 Increased 2.200 54
Cellular Assembly 
and Organization
growth of 
plasma 
membrane 
projections
1.18E-02 Increased 2.866 40
Cellular 
Movement
migration of 
tumor cells 1.26E-02 Increased 2.089 20
Cell 
Morphology
shape change 
of neurons 1.26E-02 Increased 2.205 6
Table 3: Top associated biofunctions by IPA. Top significantly tumorigenesis-
related biofunctions concerned with the ACSL4-induced transcriptome alteration 
in MCF-7 Tet-Off/ACSL4 cells. Only p-values under 0.01 calculated by right-tailed 
Fisher’s Exact test were considered significant. IPA uses the activation z-score 
algorithm to make predictions. The z-score algorithm is designed to reduce the 
chance that random data will generate significant predictions.
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recombination, repair, gene expression and cancer showed the highest score. 
In particular, the finding that cellular development and embryogenesis are 
within the top ten biofunctions is interestingly in agreement with recent 
work showing the crucial role of ACSL4 pathways in embryo development 
in zebrafish [12] and Drosophila [14,24]. 
RNA-Seq data confirmed by analysis of gene expression 
changes by real-time RT-PCR
We further validated the gene expression changes found in RNA-
Seq data and IPA by real-time RT-PCR in independent biologic repeats 
of samples from MCF-7 Tet-Off/ACSL4 and MCF-7 Tet-Off empty 
vector under the same conditions used for RNA-Seq analysis (relative 
mRNA expression levels are shown in (Figure 1). A comparison of 
fold changes between RNA-Seq and real-time RT-PCR for each gene is 
shown in Figure 2, which verifies that the real-time RT-PCR expression 
profiles were mostly in agreement with RNA-Seq data. Although 
there were small differences in the fold change values between the 
two methods of measurement, results were generally highly related 
(Spearman’s rank correlation coefficient was 0.55525 and the two-
tailed value of p was 0.00001) strongly supporting the reliability of our 
RNA-Seq analysis. We next focused our attention on categories that 
were relevant to this study, subgrouped these genes by function and 
measured an example of each of them (i.e. cytokines, transcription 
factors, growth factors, integrin family and cytoskeleton, Wnt signaling 
family, oncogenes, growth factor receptors and energy metabolism). 
Most of these genes have central roles in the biology of cancer cells 
regarding proliferation, migration and invasion. ACSL4 increased the 
Network Score Focus Molecules Top Diseases and Functions Molecules in Network
1 44 33
DNA Replication, 
Recombination, and 
Repair, Gene Expression, 
Cancer
CALCOCO1, CBX2, CBX5, CBX8, CHRNE, DIAPH2, ELF5, HIST1H3A (includes others), HIST1H4A 
(includes others), HIST2H2AA3/HIST2H2AA4, HIST2H2AC, HIST2H2BE (includes others),  
HIST2H3C (includes others), HIST3H2A, HOXD8, IL20, IL17R, IL17RC, KLF11, MSL3, MSMB, 
MT1G, NEK3, PARP10, RCC1, S100A7, SCML1, SHISA2, TEAD4, TFAP2C, TRANK1, TTC1, Vegf, 
WDR61, ZNF324B
2 43 32
Carbohydrate Metabolism, 
Small Molecule 
Biochemistry, Post-
Translational Modification
A4GALT, ATL1, B4GALT1, B4GALT5, B4GALT6, B4GALT7, CDC42EP5, CMTM8, CYP4Z1, DSC2, 
EMCN, ERK1/2, ETV4, FAIM3, Galactosyltransferase beta 1, 4, GLIPR2, HS6ST2, KLF13, LINGO1, 
LRRN1, MMD, MUC5B, NDST1, NMU, OLFM1, PKP2, RAPGEF2, RTKN, RTN4R, RTN4RL2, SHC4, 
ST6GAL1, sulfotransferase, TP53TG1, ZNF217
3 35 28
Molecular Transport, 
Hereditary Disorder, 
Neurological Disease
ANO3, AP-3, AP3B2, AP3D1, ATP6V0A4, ATP6V0B, ATP6V1C2, CBR3, DOK3, EDARADD, 
EHF, ENO3, FBXO41, H+-exporting ATPase, H+-transporting two sector ATPase, KCND3, MIB2, 
MTORC1, NFIX, NFkB (complex), PDCD11, PGM1, PNKD, PRMT2, PRPH, RFTN1, S100, S100A1, 
S100P, SGCB, SGCG, TFEB, TMOD2, Vacuolar H+ ATPase, ZNF385A
4 31 26
Cellular Development, 
Embryonic Development, 
Developmental Disorder
ADAMTS9, ADCY, ADCY6, AGPAT9, Angiotensin II receptor type 1, BIK, C8orf4, CAPN8,  DGAT2, 
EYA2, Fascin, FATE1, FSCN2, GABRB3, GGT5, GNAI1, HOXA5, INSIG2, IRS, Nr1h, NUCB1, 
p70 S6k, PADI2, PDE4D, PDE4DIP, Pkc(s), PODXL, PSCA, RGS6, SIX2, SLC1A1, SOCS, SP110, 
TPM2, TSH
5 31 26
Cardiovascular Disease, 
Cancer, Dermatological 
Diseases and Conditions
ABCC8, ABLIM1, ABLIM2, CCNG2, CRAT, DEAF1, DLX4, FOXO4, GATA6, GPX2, GUCY1A3, 
Hedgehog, Histone h4, ID3, KLF2, LMO2, Notch, NOTCH2, PI3K (family), PLEKHF1,  PTCH1, 
PTCH2, QPCT, Ras, RCN1, Secretase gamma, SLC26A2, SMAD6, SMOOTH MUSCLE ACTIN, 
TAGLN, TCF, TNNT1, TOB2, ZC3H15
6 31 26
Carbohydrate Metabolism, 
Tissue Morphology, 
Ophthalmic Disease
ACAA2, Alpha catenin, BMP7, BRSK1, BSG, CBR4, CDH8, CHST11, CLDN23, CNKSR3, collagen, 
Collagen(s), CTGF, elastase, ERBB2, estrogen receptor, FAM134B, GJB3, HSD17B, HSD17B7, 
HSD17B8, HSD17B14, Integrin, KIFC3, MAP2K1/2, Mmp, MMP23B, PLEK2, PRR15L, RNF149, 
SOWAHC, SOX4, SYNPO, TSPAN4, ZNF703
7 29 25
Cell Morphology, Hair 
and Skin Development 
and Function, Organ 
Morphology
ACHE, Akt, ANTXR1, ARHGAP24, ASAH2, CHCHD2, chymotrypsin, COL18A1, COL6A2, Collagen 
type IV, Collagen type VI, CSF2RA, EPHB4, gelatinase, GPIIB-IIIA, GSTZ1, ITGA2, ITGB4, LAMB1, 
Laminin, Laminin1, MEX3B, MGLL, mir-29, MSR1, PID1, PPT1, PTTG1IP, RAP1GAP, SCARA3, 
SCAVENGER receptor CLASS A, STARD13, TACSTD2, TNFRSF21, Vla-4
8 29 25
Cell Morphology, Cellular 
Compromise, Lipid 
Metabolism
Alpha Actinin, Alpha tubulin, Ant, ARL2BP, ASCL2, ASIC3, Beta Tubulin, calpain, CLINT1, DCDC2, 
DHRS2, DMTN, DPYSL2, ESPN, F Actin, FMNL1, Focal adhesion kinase,  GABARAPL1, MARCKS, 
Mucin, PACSIN1, SHROOM3, SLC25A4, SLC25A6, SNX33, Spectrin, STOM, Talin, TBC1D2B, 
TOMM20L, TPT1, TRDMT1, TSPO, VDAC1, WAS
9 29 25
Cancer, Dermatological 
Diseases and Conditions, 
Hematological Disease
60S ribosomal subunit, ANKRD13B, ATR, CCDC22, CCDC53, CCDC93, CKB, COL11A2, Collagen 
type II, CTSL, DNAJC27, Dynamin, E2F8, ENaC, ERRFI1, FAM21A/FAM21C, HSP, Hsp27, Hsp70, 
HSPA8, let-7, mGluR, NXT2, OPTN, p85 (pik3r), RPL39, RPLP1, RRM2, SH3GL3, TM4SF1, 
TNRC6C, TRPC1, Ubiquitin, UCHL1, ZNF219
10 29 25
Endocrine System 
Development and 
Function, Small 
Molecule Biochemistry, 
Developmental Disorder
ACPP, ACSS1, ADRB, AGBL2, ATP9A, BOK, C8G, CA4, Cg, CHST8, Creb, DIO2, EPHB6, 
FAM198B, FAM214A, FSH, Igm, KHDRBS3, Lh, LIMCH1, MAMLD1, Mek, OGFR, ONECUT1, PLC, 
PTPN21, PTTG1, RAB33B, Raf, Rap1, RETSAT, SGSM2, SLCO4A1, TP53I11, YPEL3
Table 4: Gene networks of ACSL4-overexpressing cells. RNA-Seq data were analyzed for significantly regulated functions using IPA. The genes associated with each 
function network shown in the last column are significantly regulated in the ACSL4-overexpressing cells. Score: negative exponent of p-value calculated by a right-tailed 
Fisher’s Exact test, which calculates the likelihood that network eligible molecules are found together by random chance alone.
 
Figure 2: Validation of RNA-Seq data. Correlation between RNA-Seq and 
real-time PCR data of differential gene expression from MCF-7 Tet-Off/
ACSL4 to MCF-7 Tet-Off empty vector cells. Data are presented as log2 ratios. 
Spearman's rank correlation coefficient was 0.55525 and the two-tailed value of 
p was 0.00001. By normal standards, the positive correlation between the two 
variables would be considered statistically significant.
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expression levels of  interleukin 20 IL20, Ets homologous factor (EHT), 
SP6 transcription factor (Krueppel-like factor 14 or SP6), transforming 
growth factor beta 2 (TGFβ2), V-erb avian erythroblastic leukemia viral 
oncogene homologue 2 (ERBB2), vascular endothelial growth factor 
A (VEFGA), integrin alpha 2 (ITGA2), MAP/Microtubule affinity-
regulating kinase 1 (MARK1), FXYD domain containing ion transport 
regulator 5 (FXYD5), ret proto-oncogen (RET), murine oesteosarcoma 
viral oncogene homolog (FOS), fibroblast growth factor receptor 1 
(FGFR1) and Wingless-Type MMTV Integration Site Family Member 
6 (WNT6) and WNT10A. One of the genes showing a marked decrease 
after ACSL4 expression was the WNT inhibitory factor 1 (WIF1). IL20 
has been demonstrated to be upregulated in muscle-invasive bladder 
cancer patients, while EHT and SP6 are involved in differentiation 
and carcinogenesis. The SP6 has also been proposed to contribute to 
the malignant phenotype of breast tumors. TGFβ2, ERbB2, VEFGA, 
ITGA2, MARK1, FXYD5, RET and FOS are involved in tumor 
progression as well. Other genes measured included the Unc-51-like 
autophagy-activating kinase 1 (ULK1) and the retinoic acid induced 2 
(RAI2). In short, most of the genes confirmed to be upregulated here 
have well established roles in tumorigenesis. In addition, Table 5 shows 
the top small nuclear RNA and microRNA (miR) regulated by ACSL4. 
MicroRNAs play an important role in virtually all biological pathways and 
they may hence influence numerous cancer-relevant processes. ACSL4 
upregulates miR-29a, whose overexpression has been described to increase 
tube formation and migration in endothelial cultures. Mechanistically, 
miR-29a directly targets the phosphatase and tensin homolog (PTEN) in 
endothelial cells, leading to the activation of the AKT pathway [25]. miR 
let-7, an ACSL4-downregulated miR, represses cell proliferation pathways 
in human cells and has been described as a master regulator of cell 
proliferation pathways [26]. Overall, the RNA-Seq and IPA have identified 
genes that could potentially play important roles in the regulation of 
invasion and migration of breast tumor cells in vivo. We further studied 
enriched canonical pathways and analyzed them through IPA on the 
basis of RNA-Seq data. Eukaryotic translation initiation factor 2 (EIF2), 
protein ubiquitination, ribosomal protein S6 kinase 70kDa polypeptide 1 
(p70S6K), mechanistic target of rapamycin (mTOR) and the signaling of 
molecular mechanisms of cancer are among the top canonical pathways 
triggered by ACSL4 with the lowest p-values.
Signal transduction pathways triggered by ACSL4 overexpression
In order to study the signaling pathway triggered by ACSL4 on the 
basis of RNA-Seq bioinformatic studies, we next defined a functional 
protein signature of the ACSL4 pathway by using RPPA, a high-
throughput antibody-based technique developed for functional 
proteomic studies to measure phosphorylation states, as well as total 
levels of key signaling pathway intermediaries. This RPPA used 217 
different antibodies directed to signaling proteins or directed to specific 
phosphorylated sites known to regulate protein signaling activity [22]. 
The analysis was performed on lysates derived from MCF-7 Tet-Off/
ACSL4, MCF-7 Tet-Off empty vector and doxycycline-treated MCF-7 
Tet-Off/ACSL4 cells, the latter used to specifically override ACSL4 
expression. The pattern of protein expression and/or phosphorylation 
was remarkably different between MCF-7 Tet-Off/ACSL4 and MCF-7 
Tet-Off empty vector. Lysates from doxycycline-treated MCF-7 Tet-Off/
ACSL4 cells showed a pattern similar to that of MCF-7 Tet-Off empty 
vector, further supporting the role of ACSL4 in the effects observed. 
Figures 3 and 4 show the proteins that exhibited a significant increase or 
decrease, respectively, in expression or phosphorylation status. ACSL4 
overexpression in MCF-7 breast cancer cells changed the pattern of 
expression or the pattern of phospho-dephosphorylation of about fifty 
proteins. These effects were reversed by doxycycline treatment, which 
confirms the specificity of the functional proteomic signature of ACSL4. 
We next performed a functional annotation analysis using the 
bioinformatic program DAVID on the basis of RPPA data 
Figure 5 shows the DAVID scheme of pathways in cancer. ACSL4 
overexpression stimulated the dephosphorylation of two proteins and 
the phosphorylation of thirteen proteins, among which it markedly 
Small nuclear RNA (some examples) Gene Symbol Location Change
RNA, U12 small nuclear RNU12 Nucleus Upregulated
RNA, U4 small nuclear 1 RNU4-1 Nucleus Upregulated
RNA, U4atac small nuclear 
(U12-dependent splicing) RNU4ATAC Nucleus Upregulated
RNA, U5A small nuclear 1 RNU5A-1 unknown Upregulated
RNA, U5D small nuclear 1 RNU5D-1 unknown Upregulated
RNA, U5E small nuclear 1 RNU5E-1 unknown Upregulated
small nucleolar RNA, H/ACA box 8 SNORA4 unknown Downregulated
Micro RNA (some examples) Gene Symbol Location Change
microRNA 29a miR-29 Cytoplasm Upregulated
microRNA 1290 miR-1290 Cytoplasm Upregulated
microRNA 25 miR-25 Cytoplasm Downregulated
microRNA let-7a-1 let-7 Cytoplasm Downregulated
microRNA let-7d let-7 Cytoplasm Downregulated
Table 5: Top small nuclear RNA and microRNA regulated by ACSL4. 
 
Figure 3: Identification of significantly upregulated protein expression or 
phosphorylation in ACSL4-overexpressing cells using RPPA. Proteins were 
extracted from MCF-7 Tet-Off empty vector, MCF-7 Tet-Off/ACSL4 cells and 
doxycycline treated-MCF-7 Tet-Off/ACSL4 (Doxy, 1 ug/ml, 48 h) cells, and were 
subjected to RPPA analysis. Data are presented as fold changes (only results 
with p-values under 0.05 are shown).
 
Figure 4: Identification of significantly downregulated protein expression or 
phosphorylation in ACSL4-overexpressing cells using RPPA. Proteins were 
extracted from MCF-7 Tet-Off empty vector, MCF-7 Tet-Off/ACSL4 cells and 
doxycycline treated-MCF-7 Tet-Off/ACSL4 (Doxy, 1 ug/ml, 48 h) cells, and were 
subjected to RPPA analysis. Data are presented as fold changes (only results 
with p-values under 0.05 are shown).
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stimulated the phosphorylation the mTOR pathway as previously 
described [22]. In accordance with the results mentioned above, ACSL4 
overexpression also stimulates the expression of caveolin. Caveolin-1 is 
a ubiquitously expressed scaffolding protein which is enriched in 
caveolae −i.e. subtypes of lipid rafts− and which is involved in several 
cellular functions such as endocytosis, vesicular transport and signal 
transduction. Studies also revealed that caveolin-1 is an essential 
regulator of the invadopodia-mediated degradation of extracellular 
matrix, which indicates that caveolin-1 plays an essential role in cancer 
cell invasion [27]. Indeed, at least in breast cancer cell lines, caveolin-1 
expression is predominantly observed in invasive cell lines and well 
correlated with invadopodia activity. These results correlate with those 
obtained in RNA-Seq, where cell movement showed the highest score 
(Table 3). Glycogen synthase kinase-3 alpha and beta (GSK3α and 
GSK3β), critical negative regulators of diverse signaling pathways, are 
two additional phosphoproteins whose levels exhibit an important 
increase in response to ACSL4 overexpression, and whose 
phosphorylation on Ser21 and Ser9, respectively, inhibits GSK3 activity. 
GSK3 has also been implicated in the negative regulation of FAK (focal 
adhesion kinase) activity [28]. As GSK3α has been shown to inhibit the 
Wnt signaling pathway, the inhibition of GSK3α activity by 
phosphorylation might suggest that Wnt signaling is part of the 
mechanism of action of ACSL4 overexpression. The aberrant regulation 
of the Wnt signaling pathway is a prevalent theme in cancer biology. 
From early observations that Wnt overexpression could lead to 
malignant transformation of mouse mammary tissue to the most recent 
genetic discoveries gleaned from tumor genome sequencing, the Wnt 
pathway continues to evolve as a central mechanism in cancer biology. 
Results from RNA-Seq also show that ACSL4 overexpression causes a 
strong reduction in the expression of WIF1. The protein encoded by 
this gene inhibits Wnt proteins, which are extracellular signaling 
molecules playing a role in embryonic development. Mammary cancer 
is a prominent example involving the Wnt pathway, particularly cancers 
classified as basal-like or triple-negative [29,30] which characteristically 
involve the expression of Wnt receptor FZD7 [31]. Accordingly, Yang et 
al. recently reported experiments in which knockdown of FZD7, in cell 
line models of triple-negative breast cancer, reduced the expression of 
Wnt target genes, inhibited tumorigenesis in vitro and greatly retarded 
the capacity of the MDA-MD-231 cell line to form tumors in mice [32]. 
These results suggest that Wnt ligands might drive certain breast 
cancers and are consistent with previous work from the Hynes 
laboratory [33]. In agreement with these data, ACSL4 overexpression 
increased the expression of WNT6 and WNT10A (Figure 1). The WNT6 
gene is overexpressed in cervical cancer cell lines and strongly 
coexpressed with another family member, WNT10A, in a colorectal 
cancer cell line. WNT6 overexpression may play a key role in 
carcinogenesis and is clustered with WNT10A in chromosome 2q35 
region. The Wnt pathway is also implicated in the activation of mTORC1 
through TSC1/2. In our studies, Wnt signaling inhibited GSK3β, which 
normally phosphorylates and promotes TSC2 activity, and ACSL4 
overexpression produced the stimulation of GSK3 on Ser9, which 
suggests that this mechanism of mTORC1 activation is also used by 
ACSL4 [22]. As mentioned above, ACSL4 overexpression increases the 
phosphorylation of GSK3α and β, and a requirement for ACSL4 has 
recently been demonstrated in dorsoventral pattering of zebrafish 
embryo [12] and embryogenesis and neurogenesis in Drosophila 
[14,24]. These results show that ACSL4 works through the inhibition of 
AKT-dependent GSK3 activity by increasing its phosphorylation. And, 
given the interplay between morphogenic signals in developing 
 
Figure 5: ACSL4 and pathways in cancer. Red marks highlight ACSL4-regulated genes in RPPA analysis. The pathway scheme was obtained from KEGG_PATHWAY 
database. Analysis was performed by DAVID bioinformatic tool.
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embryos, the interaction of these pathways might be expected in cancer. 
ACSL4 overexpression also stimulates the protein levels of growth 
factors and their receptors, such as the insulin-like growth factor 
binding protein (IGFBP2). Among genes involved in cell cycle control, 
ACSL4 decreases the level of the atalaxia telangiestasa (ATM) gene, a 
kinase that regulates cell cycle checkpoints by phosphorylating multiple 
proteins including histone H2AX, CHK1 and CHK2 kinases and p53. 
ATM is activated through auto- or transphosphorylation on Ser1981 
and/or Ser1893 in response to DNA damage, particularly the induction 
of DNA double-strand breaks. ACSL4 also produces a substantial 
increase in cyclin-B1, the oncogen E3 ubiquitin protein ligase (MDM2), 
the eukaryotic translation factor 4E binding protein 1 (EEF2) and the 
GRB2-associated binding protein 2 (GAB2). In the energy area, genes 
regulated are the acetyl-CoA-carboxylase alpha and beta (ACC) and the 
succinate dehydrogenase complex subunit a flavoprotein (SDHA), a 
part of the respiratory chain. ACC participate in fatty acid synthesis and 
oxidation and are phosphorylated by AMP-activated protein kinase 
(AMPK) on Ser79 to inhibit their activity. ACSL4 overexpression 
decreases the activity of AMPK and thus decreases the phosphorylation 
of ACC. Finally, another gene increased by ACSL4 is the disheveled 
segment polarity protein 3 (DVL3), a member of a multi-gene family 
which bears strong similarities with the Drosophila disheveled gene, 
which in turn encodes a cytoplasmic phosphoprotein that regulates cell 
proliferation. The idea of personalized medicine and molecular 
profiling for prognostic tests has led to a plethora of studies in the past 
10 years, in search for genetic determinants of metastasic breast cancer. 
Such studies have identified gene sets, or “signatures”, whose expression 
in primary tumors is associated with higher risk of metastasis and poor 
disease outcome for the patients. Current views on cancer cell mutations 
hold that there are two different types: driver mutations, which are 
behind cancer growth because they give tumor cells a growth advantage, 
and passenger mutations, which are just along for the ride. It has been 
suggested that ACSL4 overexpression is led by a driver mutation 
[18,34]; however, as it is capable per se of changing cancer cell 
phenotypes, ACSL4 overexpression may be thought of as a backseat 
driver factor which generates changes in gene expression and signaling 
pathways toward a highly aggressive phenotype, and which acts in 
addition to passenger mutations when the driver gene is mutated. In 
summary, this study derives an ACSL4 overexpression gene and 
functional proteomic signature which might reveal important 
information about novel mediators of breast cancer cell aggressiveness. 
Here we report that ACSL4 overexpression can trigger several different 
mechanisms to regulate the aggressiveness of breast cancer cells, 
including the pathways stimulated by growth factors, nutrients, 
cytokines and changes in energy metabolism. The major findings of the 
present study are: (a) ACSL4 overexpression induces changes in genes 
associated with tumorigenesis-related biofunctions; (b) the four 
biofunctions with the highest activation z-scores are: cell movement, 
growth and proliferation, protein and cell assembly and organization; 
(c) the inhibition of ACSL4 expression completely abolishes the changes 
observed in protein expression and phosphorylation-
dephosphorylation, which demonstrates the specificity of ACSL4 
function; (d) since ACSL4 is per se capable of changing cancer cell 
phenotype, this protein overexpression may be thought of as a backseat 
driver factor which generates changes in gene expression and signaling 
pathways toward a highly aggressive phenotype; e) as ACSL4 has been 
related to colon and hepatocellular carcinoma, besides breast carcinoma, 
the present findings suggest novel mediators, specifically for combined 
pharmacological treatment toward tumor growth inhibition. Altogether, 
the present results open the possibility to use the inhibition of ACSL4 as 
a therapeutic tool in combination with agents targeting key molecular 
elements involved in breast cancer. In addition, ACSL4 could be used as 
a predictive marker that may provide the basis for patient therapy.
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Table S1. Detailed list of genes regulated by ACSL4 within the top three biofunctions by IPA. 
 
Category 
Diseases or 
Functions 
Annotation 
p-value 
Predicted 
Activation 
State 
Activation 
z-score 
Molecules 
 
# Molecules 
Cellular 
Movement 
cell 
movement 3.97E-07 Increased 4.685 
 
ABCC4, ACSL4, ADARB1, ADORA1, ANXA3, APOE, AREG/AREGB, 
ARHGAP24, ARHGAP8/PRR5-ARHGAP8,  ASCL1, B4GALT1, BAI1, BMP7, 
BSG, BTC, CADPS2, CAMK1D, CCR1, CD82,  CDKN2A, CEBPA, CELF3, 
CHRD, CHST10, CMTM8, CNTNAP2, COL18A1, CSF2RA, CTGF, CTNND2, 
CTSL, CXCL17, DCDC2, DDX58, DGCR6L, DIAPH2, DLX1, DLX2, DPYSL2, 
DYRK1B, EDN2, EFNA1, EFNB3, EGFL7, EHF, EPHB4, ERBB2, ERRFI1, ETV4, 
ETV6, F2RL1, FGFR1, FGFR4, FHL1, FLT3LG, FOS, FOXO4, FURIN, GATA6, 
GCNT1, GGT5, GLIPR2, GNAI1, GPR173, GPR56, GRB7, GRN, GUCY1A3, 
HCAR2, HLA-G, HPGD, HSPA1A/HSPA1B, HSPB1, ID2, ID3, IGFBP5, IGSF8, 
IL20, IL24, IL6R, IL6ST, INSR, IRF6, IRF7, ITGA2, ITGB4, KLF2, LAMB1, let-7, 
MAFB, MAPK10, MARCKS,  MARK1, MATK, MGLL, mir-29, MSR1, MT-ND1, 
MZF1, NCOA4, NDRG1, NDST1, NEURL, NFIX, NMU, NOD1, NOTCH2, NQO1, 
NTN1, NTRK3, ONECUT1, P2RX4, PARP9, PDCD4, PDE4D, PDE4DIP, PGR, 
PLD1, PODXL, PPP3CC, PREX1, PRMT2, PTGDR2, PTTG1, QPCT, RAP1GAP, 
RAPGEF1, RAPGEF2, REPS2, RET, RHOBTB2, RHOU, RNF144A, RPS6KA1, 
S100A1, S100A12, S100A7, S100A8, S100A9, S100P, SCARB1, SCPEP1, 
SDC1, SH3PXD2B, SHC4, SKI, SLPI, SOCS2, SORBS3, SORD, SPHK1, 
SPRY4, ST6GAL1, STARD13, SYK, TACSTD2, TAZ, TENC1, TERC, TFAP2C, 
TGFB1I1, TGFB2, THBD, THRA, TM4SF1, TMSB10/TMSB4X, TNFRSF11B, 
TNFRSF21, TNFSF9, TNS1, TP73, TPT1, TRPC1, TSPO, VASH1, VAV1, VIPR1, 
VIPR2, WAS, WNT10B, ZNF217, ZSCAN1 
 
182 
Cellular 
Movement 
migration of 
cells 4.65E-07 Increased 4.677 
 
ABCC4, ACSL4, ADARB1, ADORA1, ANXA3, APOE, AREG/AREGB, 
ARHGAP24, ARHGAP8/PRR5-ARHGAP8,  ASCL1, B4GALT1, BAI1,  BMP7, 
BSG, BTC, CADPS2, CAMK1D,  CCR1, CD82,  CDKN2A, CEBPA, CHRD, 
CHST10, CMTM8, CNTNAP2, COL18A1, CSF2RA, CTGF, CTSL, CXCL17, 
DCDC2, DDX58, DGCR6L, DIAPH2, DLX1, DLX2, DPYSL2, DYRK1B, EDN2, 
EFNA1, EFNB3, EGFL7, EHF, EPHB4, ERBB2, ERRFI1, ETV4, ETV6, F2RL1, 
FGFR1, FHL1, FLT3LG, FOXO4, FURIN, GATA6, GCNT1, GGT5, GLIPR2, 
GNAI1, GPR173, GPR56, GRB7, GRN, GUCY1A3, HCAR2, HLA-G, HPGD, 
HSPA1A/HSPA1B, HSPB1, ID2, ID3, IGFBP5, IGSF8, IL20, IL24, IL6R, IL6ST, 
INSR, IRF6, IRF7, ITGA2, ITGB4, KLF2, LAMB1, let-7, MAFB, MAPK10, 
MARCKS, MARK1, MATK, MGLL, mir-29, MSR1, MT-ND1, MZF1, NDRG1, 
NDST1, NFIX, NMU, NOD1, NOTCH2, NQO1, NTN1, NTRK3, ONECUT1, 
P2RX4, PARP9, PDCD4, PDE4D, PDE4DIP, PGR, PLD1, PODXL, PREX1, 
PRMT2, PTGDR2, PTTG1, QPCT, RAP1GAP, RAPGEF1, RAPGEF2, REPS2, 
RET, RHOBTB2, RHOU, RNF144A, S100A12, S100A7, S100A8, S100A9, 
S100P, SCARB1, SCPEP1, SDC1, SH3PXD2B, SHC4, SLPI, SORBS3, SPHK1, 
SPRY4, ST6GAL1, SYK, TACSTD2, TAZ, TENC1, TERC, TFAP2C, TGFB1I1, 
TGFB2, THBD, TM4SF1, TMSB10/TMSB4X, TNFRSF11B, TNFRSF21, TNFSF9, 
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TNS1, TP73, TPT1, TRPC1, TSPO, VASH1, VAV1, VIPR1, WAS, WNT10B, 
ZSCAN1 
 
Cellular 
Growth and 
Proliferation 
proliferation 
of cells 2.04E-06 Increased 2.390 
 
ABCC4, ABTB1, ACHE, ACPP, ACSL4, ACSL6, ADAMTS9, ADARB1, ADC, 
ADIPOR2, ADORA1, AFAP1L2, AGTRAP, ANO3, ANTXR1, ANXA6, APOD, 
APOE, AREG/AREGB, ARHGAP24, ARHGEF2, ARL2BP, ASAH2, ASCL1, 
ASCL2, ATP8A2, ATR, B4GALT1, B4GALT6, B4GALT7, BAI1, BIK, BMP7, BSG, 
BST2, BTC, BTG3, C1QL4, C8orf4, CACFD1, CACUL1, CBX2, CCNG2, CCR1, 
CD82, CDKN2A, CEBPA, CHRD, CHST11, CISH, COL18A1, COL6A2, CSF2RA, 
CTGF, CTNND2, CTSL, CUX2, DDX58, DEGS2, DIRAS1, DLX2, DLX4, DOK3, 
DOT1L, DUSP2, DYRK1B, E2F8, EDN2, EFNA1, EFNB3, EHF, EIF4B, ELF5, 
ENPEP, EPHB4, EPHB6, ERBB2, ERRFI1, ETV6, EXOSC4, F2RL1, FBXO9, 
FGFR1, FGFR4, FHL1, FLT3LG, FOS, FOXD2, FOXO4, FOXP2, FSTL3, FURIN, 
G3BP1, GABARAPL1, GABRP, GATA6, GCNT1, GGT5, GLUL, GNAI1, GOLM1, 
GPR56, GPRC5C, GPX2, GRB7, GRM4, GRN, GSX2, GTPBP1, HDAC4, 
HDAC5, HINT1, HIST1H2BH/HIST1H2BO, HLA-E, HOXA5, HPGD, HR, HS6ST2, 
HSPA1A/HSPA1B, HSPA8, ID2, ID3, IFLTD1, IGFBP5, IL20, IL24, IL6R, IL6ST, 
INHA, INPP5K, INSIG1, INSR, IRF6, ISG15, ISG20, ITGA2, ITGB4, KCND3, 
KIF1A, KIF26A, KLF11, KLF13, KLF2, KLF6, LAMB1, LDLRAP1, let-7, LMO1, 
LMO2, LRRN1, LSMD1, LTBP1, MAFA, MAFB, MAFF, MAGED4/MAGED4B, 
MANF, MAP3K3, MAPK10, MATK, MINPP1, mir-25, mir-29, MSH3, MSMB, 
MSR1, MT2A, MZF1, NAB1, NCOA4, NDRG1, NEIL1, NEURL, NFIX, NOTCH2, 
NPDC1, NQO1, NR3C1, NTN1, NTRK3, OAS3, OGFR, OPTN, PALM, PARP10, 
PARP14, PDCD4, PDE4D, PDZK1, PERP, PGR, PHF6, PLD1, POR, PPT1, 
PRICKLE2, PRKAR1B, PSCA, PTCH1, PTPN22, PTTG1, QPCT, RAP1GAP, 
RAPGEF1, RAPGEF2, RASL10A, RBM38, RET, RHOBTB2, RHOU, 
RNASEH2B, RPS6KA1, RRM2, RTKN, RTN4R, RYK, S100A1, S100A13, 
S100A7, S100A8, S100A9, S100P, SCARB1, SCPEP1, SCUBE3, SDC1, 
SH3GL3, SIX2, SKI, SLC19A1, SLC25A4, SLC25A6, SLC26A2, SLPI, SMAD6, 
SNAI3, SOCS2, SOS1, SOX4, SP110, SP6, SPHK1, SPRY4, ST5, ST6GAL1, 
STARD10, STARD13, STAT2, SUV39H1, SYK, TACC1, TACSTD2, TAGLN, 
TAZ, TEAD4, TENC1, TERC, TFAP2C, TGFB1I1, TGFB2, THBD, THG1L, THRA, 
TMEM2, TMSB10/TMSB4X, TNFRSF11B, TNFRSF21, TNFSF9, TOB2, TP53I11, 
TP73, TPM2, TPT1, TRADD, TRIM21, TRPC1, TSPO, TXNIP, TXNRD2, 
UBE2L6, UCHL1, USP18, VANGL1, VASH1, VAV1, VDAC1, VIPR1, WAS, 
WNT10B, WNT6, WNT9A, YPEL3, ZNF217, ZSCAN1, ZSCAN18 
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Figure S1. Chromosome distribution patterns of differentially expressed genes and gene clusters of ACSL4-overexpressing cells.  
The analysis was performed with the CROC program (http://metagenomics.uv.es/CROC) and results were corrected by the Benjamini & Hochberg multiple 
test correction method. The minimum number of genes per cluster was 3 and the reference type of statistical analysis was by chromosome. 
>> Stats 
User genes found in reference genome 960 
Number of Unknown genes 1183 
Number of clusters found 52 
Total number of genes in clusters 508 
Number of user genes in clusters 181 
>> Chromosomes 
Chrom Clusters Genes In user set 
chr1 8 2107 119 
 
chr10 1 812 29 
 
chr11 3 1364 53 
 
chr12 5 1056 58 
 
chr15 1 655 31 
 
chr16 2 900 27 
 
chr17 4 1230 65 
 
chr19 2 1453 58 
 
chr2 3 1356 78 
 
chr20 4 577 28 
 
chr22 1 538 29 
 
chr3 3 1096 43 
 
chr4 3 777 48 
 
chr5 3 893 51 
 
chr6 3 1087 49 
 
chr7 2 1024 46 
 
chr8 1 732 32 
 
chr9 3 848 48 
 
 
 
>> Clusters 
Chr Begin End p-value Genes Plot 
chr1 850393 939718 5.20e-03 
SAMD11 
C1orf170 
ISG15 
chr1 6231988 6502158 5.20e-03 PLEKHG5 GPR153 ESPN 
 
chr1 33132996 33733660 5.20e-03 
TMEM54 ADC 
TRIM62 
ZSCAN20 
 
chr1 148051453 148126090 1.92e-07 
HIST2H3D 
HIST2H2AA4 
HIST2H3C 
HIST2H2AC 
HIST2H2AA3 
HIST2H2AB 
HIST2H2BE 
HIST2H3A 
 
chr1 151597384 151698113 2.97e-04 
S100A7 
S100A12 
S100A8 
S100A9 
 
chr1 158017515 158179898 5.20e-03 
DUSP23 
CCDC19 
IGSF9 
 
chr1 205105821 205161822 5.20e-03 FAIM3 IL20 IL24 
 
chr1 208028391 208482302 5.20e-03 
C1orf133 
SERTAD4 
IRF6 
 
chr10 105148174 105340116 1.30e-03 
NEURL 
PDCD11 
CALHM2 
 
chr11 301317 480579 1.74e-03 IFITM1 IFITM3 PTDSS2 
 
chr11 44572789 45789459 1.74e-03 
SYT13 
TP53I11 
SLC35C1 
CD82 
 
chr11 120828251 122437242 1.74e-03 
SORL1 
C11orf63 
HSPA8 
 
chr12 2974194 3809442 4.71e-03 
TEAD4 
TSPAN9 
PARP11 
 
chr12 11694329 12565299 4.71e-03 
ETV6 
MANSC1 
DUSP16 
 
chr12 47975251 48031549 4.71e-03 DNAJC22 PRPH C1QL4 
 
chr12 103375320 105056561 4.71e-03 
CHST11 
SLC41A2 
NUAK1 
 
chr12 111829228 111932669 4.71e-03 OAS2 OAS1 OAS3 
 
chr15 86221173 86999763 2.96e-03 NTRK3 DET1 ISG20 
 
chr16 55702156 55875953 7.80e-04 ARL2BP CPNE2 PLLP 
 
chr16 56104157 56389656 7.80e-04 CCDC102A GPR56 KIFC3 
 
chr17 39741622 39936264 4.24e-03 
RUNDC3A 
GRN 
GPATCH8 
 
chr17 40655275 40915633 4.24e-03 
ARHGAP27 
FMNL1 
PLEKHM1 
 
chr17 45401832 45557322 4.24e-03 SAMD14 DLX4 PDK2 
 
chr17 70979582 71134156 4.24e-03 
KIAA0195 
CASKIN2 
MYO15B 
 
chr19 1988741 2180788 1.89e-03 
DOT1L 
MKNK2 
AP3D1 
 
chr19 63144107 63332682 1.89e-03 
ZSCAN18 
ZNF256 
ZNF329 
ZSCAN1 
 
chr2 6907435 8740477 5.42e-03 RNF144A CMPK2 ID2 
 
chr2 19960232 20288109 5.42e-03 MATN3 TTC32 SDC1 
 
chr2 220117694 220214691 3.11e-04 
TMEM198 
SLC4A3 INHA 
OBSL1 
 
chr20 38749936 39420917 3.15e-03 LPIN3 ZHX3 MAFB 
 
chr20 42676612 42872326 3.15e-03 KCNK15 PKIG RIMS4 
 
chr20 45040678 46877804 3.15e-03 
EYA2 
ZMYND8 
PREX1 
 
chr20 54638008 55416305 3.15e-03 RBM38 TFAP2C BMP7 
 
chr22 41226621 41889018 4.27e-03 
TSPO SERHL 
SERHL2 
A4GALT BIK 
 
chr3 31678571 32386460 1.77e-03 
OSBPL10 
ZNF860 
CMTM8 
 
chr3 123729904 123930131 1.77e-03 
PARP15 
PARP14 
PARP9 
 
chr3 128867472 129609789 1.77e-03 ABTB1 MGLL EEFSEC 
 
chr4 75529927 76708670 3.93e-04 BTC AREGB C4orf26 AREG 
 
chr4 77576230 78325283 6.51e-03 
ANKRD56 
SHROOM3 
CCNG2 
 
chr4 89402774 89646049 6.51e-03 
PPM1K 
HERC6 
HERC5 
 
chr5 52321056 53642030 5.23e-03 ARL15 MOCS2 ITGA2 
 
chr5 79819699 80207434 5.23e-03 
ANKRD34B 
MSH3 
FAM151B 
 
chr5 157091027 159788263 2.92e-04 
THG1L LSM11 
CLINT1 
PTTG1 
PWWP2A 
SLU7 CCNJL 
TTC1 UBLCP1 
 
chr6 21702745 24466098 2.65e-03 DCDC2 SOX4 KAAG1 
 
chr6 26324473 26393706 1.16e-04 
HIST1H1D 
HIST1H2BI 
HIST1H2BG 
HIST1H2BH 
HIST1H3F 
HIST1H4H  
chr6 27883286 27907284 1.16e-04 
HIST1H2AJ 
HIST1H4K 
HIST1H2BL 
HIST1H4J 
 
chr7 99743445 99913597 2.62e-03 
TSC22D4 
MEPCE 
AC005071.2 
PILRA 
 
chr7 100239022 100519578 2.62e-03 
TRIM56 ACHE 
MUC3A 
EPHB4 
 
chr8 143542562 143813856 2.36e-03 BAI1 PSCA C8orf55 
 
chr9 94778360 94915207 5.08e-03 FGD3 SUSD3 C9orf89 
 
chr9 129414504 129537384 5.08e-03 
TOR2A 
STXBP1 
PTRH1 
 
chr9 138456031 138701630 5.08e-03 
EGFL7 
SEC16A 
AGPAT2 
 
 
 
 
 
 
Figure S2. Top ranked networks identified by IPA from ACSL4-overexpressing cells. 
Networks are displayed graphically as nodes (genes/gene products) and edges (biological relationships between the nodes). Intensity of the node color 
indicates the degree of regulation (red: upregulation, green: downregulation, white: not differentially expressed but related to this network). 
 
 
  
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
  
 
 
 
 
